BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20974206)

  • 41. Long-term post transplant alloantibody monitoring: a single center experience.
    Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
    Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
    Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
    Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.
    Lefaucheur C; Suberbielle-Boissel C; Hill GS; Nochy D; Andrade J; Antoine C; Gautreau C; Charron D; Glotz D
    Contrib Nephrol; 2009; 162():1-12. PubMed ID: 19001809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay.
    Billen EV; Christiaans MH; Lee J; van den Berg-Loonen EM
    Transplantation; 2009 Feb; 87(4):563-9. PubMed ID: 19307795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Cardarelli F; Pascual M; Tolkoff-Rubin N; Delmonico FL; Wong W; Schoenfeld DA; Zhang H; Cosimi AB; Saidman SL
    Transpl Int; 2005 May; 18(5):532-40. PubMed ID: 15819801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
    Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
    J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome.
    Varnavidou-Nicolaidou A; Iniotaki-Theodoraki AG; Doxiadis II; Georgiou D; Patargias T; Stavropoulos-Giokas C; Kyriakides G
    Hum Immunol; 2005 Sep; 66(9):985-8. PubMed ID: 16360838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches.
    Song EY; Lee YJ; Hyun J; Kim YS; Ahn C; Ha J; Kim SJ; Park MH
    Ann Lab Med; 2012 Mar; 32(2):139-44. PubMed ID: 22389881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure.
    Cai J; Terasaki PI; Anderson N; Lachmann N; Schönemann C
    Transplantation; 2009 Jul; 88(2):226-30. PubMed ID: 19623018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
    Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
    Mujtaba MA; Fridell JA; Higgins N; Sharfuddin AA; Yaqub MS; Kandula P; Chen J; Mishler DP; Lobashevsky A; Book B; Powelson J; Taber TE
    Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.
    Seveso M; Bosio E; Ancona E; Cozzi E
    Contrib Nephrol; 2009; 162():87-98. PubMed ID: 19001816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
    Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
    Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients.
    Mujtaba MA; Goggins W; Lobashevsky A; Sharfuddin AA; Yaqub MS; Mishler DP; Brahmi Z; Higgins N; Milgrom MM; Diez A; Taber T
    Clin Transplant; 2011; 25(1):E96-102. PubMed ID: 20977497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection.
    Hirai T; Kohei N; Omoto K; Ishida H; Tanabe K
    Transpl Int; 2012 Sep; 25(9):925-34. PubMed ID: 22764746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.